ARCHIVES

New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 5 | May 30, 2014

Download PDF Visit The Full Archive

Related Articles

Bernard Fisher Says Mistake Was Not Publishing Sooner

April 22, 1994

IARC Director Denies NCI Staff Interference With Monograph

May 28, 1982

NCI Ponders Options for Implementing NCAB Changes In Organ Site Program

June 4, 1982

FDA Pettiness Holds Up Trials with Promising Anticancer Drugs

November 14, 1975

Efaproxyn Improved Survival Of Patients With Brain Mets

October 29, 2004

ODAC Recommends Fludarabine Approval for Refractory CLL

September 21, 1990